TAK-259 is a Novel, Selective, and orally bioavailable α1D Adrenoceptor Antagonist (α1D, Ki = 1.1 nM) with Anti-urinary Frequency Effects and Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. TAK-259 exhibited a larger MRTpo value and potent antiurinary frequency efficacy. TAK-259 is selected as a clinical candidate. TAK-259 represents a promising novel therapeutic agent for the treatment of OAB symptoms. References: Sakauchi N, Kohara Y, Sato A, Suzaki T, Imai Y, Okabe Y, Imai S, Saikawa R, Nagabukuro H, Kuno H, Fujita H, Kamo I, Yoshida M. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259), as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Anti-urinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. J Med Chem. 2016 Mar 8. [Epub ahead of print] PubMed PMID: 26954848.

纯度：≥98%

CAS：1192347-42-4